Anemia Autoimmune Hemolytic Anemia
Conditions
Interventions
Patients will receive C1-inh: 6000 Units before the transfusion and thereafter
3000U, 2000U and 1000U every 12 hours
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: * Positive (*1+) monospecific antiglobulin test for C3b and/or C3d with/without positivity for IgM OR strongly positive (*3+) monospecific antiglobulin test for C3b and/or C3d with positivity for IgG * Indication for a transfusion with at least 2 red packed cell concentrates based on the clinical assessment by the hematologist in charge * Hemoglobin value at least
Exclusion criteria
Exclusion criteria: * History of arterial and/or venous thromboembolic events in the absence of an actual treatment with Vitamin K-antagonists * Concomitant use of therapeutic doses of heparin * Female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives only are not acceptable. * Patients with known HIV seropositivity or chronic active hepatitis * Patients who have any severe and/or uncontrolled medical condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * improvement of the recovery of RBC transfusion- as defined as a decrease of hemoglobin | — |
Secondary
| Measure | Time frame |
|---|---|
| * Inhibition of the pro-inflammatory response | — |
Countries
Netherlands
Outcome results
None listed